Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction

Schizophrenia Research

Volumn 84, Issue 1, 2006, Pages 1-14

  Zhao, Zhong ^a   Ksiezak Reding, Hanna ^a   Riggio, Silvana ^a   Haroutunian, Vahram ^a   Pasinetti, Giulio M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Akt; Glycogen synthase kinase 3 ; Glycogen synthase kinase 3 ; Insulin receptor; Insulin resistance; Prefrontal cortex; Schizophrenia

Indexed keywords

CLOZAPINE; GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR BETA; NEUROLEPTIC AGENT; PROTEIN KINASE B; RECEPTOR SUBTYPE; SERINE; UNCLASSIFIED DRUG;

AGED; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL SCIENCE; BRAIN TISSUE; CADAVER; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SYNTHESIS; MALE; MEDICAL ASSESSMENT; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RECEPTOR INTRINSIC ACTIVITY; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STARTLE REFLEX;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIPSYCHOTIC AGENTS; BRAIN; CARRIER PROTEINS; CLOZAPINE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; INCIDENCE; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, INSULIN; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STARTLE REACTION;

EID: 33646517484     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.02.009     Document Type: Article

References (66)

1. Adams P.F., and Marano M.A. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat. 10 193 (1995) 1-260
2. Arnold S.E., Talbot K., and Hahn C.G. Neurodevelopment, neuroplasticity, and new genes for schizophrenia. Prog. Brain Res. 147 (2005) 319-345
3. Braff D.L., Grillon C., and Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry 49 (1992) 206-215
4. Bruning J.C., Gautam D., Burks D.J., Gillette J., Schubert M., Orban P.C., Klein R., Krone W., Muller-Wieland D., and Kahn C.R. Role of brain insulin receptor in control of body weight and reproduction. Science 289 (2000) 2122-2125
5. Bushe C., and Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br. J. Psychiatr. Suppl. 47 (2004) S67-S71
6. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Steelman L.S., Blalock W.L., Franklin R.A., and McCubrey J.A. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17 (2003) 590-603
7. Chen B., Wang J.F., Hill B.C., and Youngm L.T. Lithium and valproate differentially regulate brain regional expression of phosphorylated CREB and c-Fos. Brain Res. Mol. Brain Res. 70 (1999) 45-53
8. Cho H., Thorvaldsen J.L., Chu Q., Feng F., and Birnbaum M.J. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276 (2001) 38349-38352
9. Coffer P.J., Jin J., and Woodgett J.R. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 335 (1998) 1-13
10. Dajani R., Fraser E., Roe S.M., Yeo M., Good V.M., Thompson V., Dale T.C., and Pearl L.H. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J. 22 (2003) 494-501
11. Dirks A., Groenink L., Westphal K.G., Olivier J.D., Verdouw P.M., van der Gugten J., Geyer M.A., and Olivier B. Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs. Neuropsychopharmacology 28 (2003) 1790-1798
12. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., and Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 26 (2000) 903-912
13. Doble B.W., and Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell. Sci. 116 (2003) 1175-1186
14. Dwyer D.S., Pinkofsky H.B., Liu Y., and Bradley R.J. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog. Neuro-psychopharmacol. Biol. Psychiatry 23 (1999) 69-80
15. Dwyer D.S., Bradley R.J., Kablinger A.S., and Freeman III A.M. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann. Clin. Psychiatry 13 (2001) 103-113
16. Dwyer D.S., Lu X.H., and Bradley R.J. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res. 971 (2003) 31-39
17. Dynes J.B. Cause of death in schizophrenia. Behav. Neuropsychiatry 1 (1969) 12-14
18. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 8 (2002) 126-132
19. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., and Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 36 (2004) 131-137
20. Felker B., Yazel J.J., and Short D. Mortality and medical comorbidity among psychiatric patients: a review. Psychiatr. Serv. 47 (1996) 1356-1363
21. Franke T.F., Kaplan D.R., Cantley L.C., and Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275 (1997) 665-668
22. Fuster J.M. The prefrontal cortex-an update: time is of the essence. Neuron 30 (2001) 319-333
23. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., and Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15 (2001) 1406-1418
24. Gould T.J., Bizily S.P., Tokarczyk J., Kelly M.P., Siegel S.J., Kanes S.J., and Abel T. Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha. Neuropsychopharmacology 29 (2004) 494-501
25. Havrankova J., Schmechel D., Roth J., and Brownstein M. Identification of insulin in rat brain. Proc. Natl. Acad. Sci. U. S. A. 75 (1978) 5737-5741
26. Hemmings B.A. Akt signaling: linking membrane events to life and death decisions. Science 275 (1997) 628-630
27. Henderson D.C., Nguyen D.D., Copeland P.M., Hayden D.L., Borba C.P., Louie P.M., Freudenreich O., Evins A.E., Cather C., and Goff D.C. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J. Clin. Psychiatry 66 (2005) 1116-1121
28. Henderson D.C., Cagliero E., Copeland P.M., Borba C.P., Evins E., Hayden D., Weber M.T., Anderson E.J., Allison D.B., Daley T.B., Schoenfeld D., and Goff D.C. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch. Gen. Psychiatry 62 (2005) 19-28
29. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., and Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18 (2004) 902-904
30. Itoh K., Tang T.L., Neel B.G., and Sokol S.Y. Specific modulation of ectodermal cell fates in Xenopus embryos by glycogen synthase kinase. Development 121 (1995) 3979-3988
31. Jiang Z.Y., Zhou Q.L., Coleman K.A., Chouinard M., Boese Q., and Czech M.P. Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7569-7574
32. Jope R.S., and Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29 (2004) 95-102
33. Katsel P., Davis K.L., Gorman J.M., and Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr. Res. 77 (2005) 241-252
34. Katsel P.L., Davis K.L., and Haroutunian V. Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. Int. Rev. Neurobiol. 63 (2005) 41-82
35. Kelly A., and Lynch M.A. Long-term potentiation in dentate gyrus of the rat is inhibited by the phosphoinositide 3-kinase inhibitor, wortmannin. Neuropharmacology 39 (2000) 643-651
36. Kobayashi M., Nagata S., Kita Y., Nakatsu N., Ihara S., Kaibuchi K., Kuroda S., Ui M., Iba H., Konishi H., Kikkawa U., Saitoh I., and Fukui Y. Expression of a constitutively active phosphatidylinositol 3-kinase induces process formation in rat PC12 cells. Use of Cre/loxP recombination system. J. Biol. Chem. 272 (1997) 16089-16092
37. Kozlovsky N., Belmaker R.H., and Agam G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am. J. Psychiatry 157 (2000) 831-833
38. Kozlovsky N., Belmaker R.H., and Agam G. Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr. Res. 52 (2001) 101-105
39. Kozlovsky N., Amar S., Belmaker R.H., and Agam G. Psychotropic drugs affect Ser9-phosphorylated GSK-3beta protein levels in rodent frontal cortex. Int. J. Neuropsychopharmacol. 9 (2005) 1-6
40. Ksiezak-Reding H., Pyo K., Feinstein B., and Pasinetti G.M. Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro. Biochim. Biophys. Acta, Mol. Basis Dis. 1639 (2003) 159-168
41. Li B.S., Ma W., Jaffe H., Zheng Y., Takahashi S., Zhang L., Kulkarni A.B., and Pant H.C. Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J. Biol. Chem. 278 (2003) 35702-35709
42. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., Cooper T.B., Chakos M., and Lieberman J.A. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry 160 (2003) 290-296
43. Lu X.H., Bradley R.J., and Dwyer D.S. Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res. 1011 (2004) 58-68
44. Mackin P., Watkinson H., and Young M. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48 (2005) 215-221
45. Mandelkow E.M., Stamer K., Vogel R., Thies E., and Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 24 (2003) 1079-1085
46. Markus A., Zhong J., and Snider W.D. Raf and akt mediate distinct aspects of sensory axon growth. Neuron 35 (2002) 65-76
47. Meltzer H.Y., Perry E., and Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr. Res. 59 (2003) 19-27
48. Mukherjee S., Schnur D.B., and Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1 (1989) 495
49. Mukherjee S., Decina P., Bocola V., Saraceni F., and Scapicchio P.L. Diabetes mellitus in schizophrenic patients. Compr. Psychiatry 37 (1996) 68-73
50. Nadri C., Kozlovsky N., Agam G., and Bersudsky Y. GSK-3 parameters in lymphocytes of schizophrenic patients. Psychiatry Res. 112 (2002) 51-57
51. Numakawa T., Yagasaki Y., Ishimoto T., Okada T., Suzuki T., Iwata N., Ozaki N., Taguchi T., Tatsumi M., Kamijima K., Straub R.E., Weinberger D.R., Kunugi H., and Hashimoto R. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum. Mol. Genet. 13 (2004) 2699-2708
52. Okamoto H., and Accili D. In vivo mutagenesis of the insulin receptor. J. Biol. Chem. 278 (2003) 28359-28362
53. Olivier B., Leahy C., Mullen T., Paylor R., Groppi V.E., Sarnyai Z., and Brunner D. The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?. Psychopharmacology (Berl.) 156 (2001) 284-290
54. Plotkin B., Kaidanovich O., Talior I., and Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J. Pharmacol. Exp. Ther. 305 (2003) 974-980
55. Ryan M.C., Collins P., and Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 160 (2003) 284-289
56. Sanna P.P., Cammalleri M., Berton F., Simpson C., Lutjens R., Bloom F.E., and Francesconi W. Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region. J. Neurosci. 22 (2002) 3359-3365
57. Schubert M., Gautam D., Surjo D., Ueki K., Baudler S., Schubert D., Kondo T., Alber J., Galldiks N., Kustermann E., Arndt S., Jacobs A.H., Krone W., Kahn C.R., and Bruning J.C. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3100-3105
58. Spurney C.F., Baca S.M., Murray A.M., Jaskiw G.E., Kleinman J.E., and Hyde T.M. Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse 34 (1999) 266-276
59. Stambolic V., Ruel L., and Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 6 (1996) 1664-1668
60. Sulis M.L., and Parsons R. PTEN: from pathology to biology. Trends Cell Biol. 13 (2003) 478-483
61. Swerdlow N.R., and Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 24 (1998) 285-301
62. Takeda K., Toda K., Saibara T., Nakagawa M., Saika K., Onishi T., Sugiura T., and Shizuta Y. Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency. J. Endocrinol. 176 (2003) 237-246
63. Tarantino L.M., Gould T.J., Druhan J.P., and Bucan M. Behavior and mutagenesis screens: the importance of baseline analysis of inbred strains. Mamm. Genome 11 (2000) 555-564
64. Turner B.J., Rembach A., Spark R., Lopes E.C., and Cheema S.S. Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice. J. Neurosci. Res. 74 (2003) 605-613
65. Wang Q., Liu L., Pei L., Ju W., Ahmadian G., Lu J., Wang Y., Liu F., and Wang Y.T. Control of synaptic strength, a novel function of Akt. Neuron 38 (2003) 915-928
66. Zarate J.M., Boksa P., Baptista T., and Joober R. Effects of clozapine on behavioral and metabolic traits relevant for schizophrenia in two mouse strains. Psychopharmacology (Berl.) 171 (2004) 162-172